2022 - Royal Emerald Pharmaceutical Research & Development DBA Royal Emerald Pharmaceutical


Drug Enforcement Administration

Importer of Controlled Substances Registration

[DRG No. 22-312]

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of registration.

SUMMARY: The registrant listed below has applied for and been granted a registration by the Drug Enforcement Administration (DEA) as an importer of a schedule I controlled substance.

SUPPLEMENTARY INFORMATION: The company listed below applied to be registered as an importer of a schedule I controlled substance(s). Information on a previously published notice is listed below. No comments or objections were submitted and no requests for a hearing were submitted for this notice.

Company FR Docket Published
Royal Emerald Pharmaceuticals Research and Development
DBA Royal Emerald Pharmaceuticals
86 FR 17642 April 5, 2021

DEA has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrant to import the applicable basic class of a schedule I controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA investigated each of the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, DEA has granted a registration as an importer for a schedule I controlled substance to the above listed company.

Dated: 1/14/2022

Brian S. Besser,
Acting Assistant Administrator.